CTLA4 and metastatic melanoma: For instance, high blood butyrate and propionate levels were reported to be associated with resistance to CTLA-4 blockade in patients with metastatic melanoma, and oral administration of sodium butyrate diminished antitumor efficacy of anti-CTLA-4 in mice51.